Benign Prostatic Hyperplasia
Conditions
Brief summary
This study is an open-label, randomized, fasted, single dose, crossover study to evaluate the bioequivalence of Chong Kun Dang Pharmaceutical Chong Kun Dang Tamsulosin HCl Tablet and Astellas Phama Korea Inc. Harnal-D in healthy volunteers
Detailed description
To healthy subjects of thirty (30), following treatments are administered dosing in each period and wash-out period is a minimum of 1 week. Reference drug: Harnal-D Tab. / Test drug: Chong Kun Dang Tamsulosin HCl Tab. Pharmacokinetic blood samples are collected up to 48hrs. The pharmacokinetic characteristics and safety are assessed.
Interventions
DRUGHarnal-D Tab.
Harnal-D Tab. 1T single oral administration under fasting
Chong Kun Dang Tamsulosin HCl Tab. 1T single oral administration under fasting condition
Sponsors
Chong Kun Dang Pharmaceutical
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
MALE
Age
19 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
1. Healthy subject older than 19 years men at the screening 2. Individuals without congenital/chronic diseases and without abnormal symptoms or diagnosis based on a medical examination(if necessary, EEG, ECG, chest X-ray, endoscope or upper gastrointestinal radiography) 3. Individuals who were deemed to be appropriate as study subjects in accordance with the screening results (laboratory tests, ECG etc.) 4. Individuals who had 18 kg/m2 ≤ Body Mass Index(BMI) ≤ 30kg/m2 \* BMI = Weight(kg)/ Height(m)2 5. Individuals who had agreed to participate in the study 6. Individuals without mental illness history within five year prior to the screening 7. Individuals without a medical history of gastrointestinal operations that may affect drug absorption 8. Individuals who do not agree to the approved methods of double contraception and using spermicide for up to 7 days after investigational product(s) administration
Exclusion criteria
1. Individuals who had enrolled to barbiturate's drugs by induction and inhibition of drug-metabolizing enzymes of drugs within the 1 month 2. Individuals who had excessive drinking within the 1 month \*Men: 21 glasses/week exceeded(1 glass: distilled spirits 45 mL, wine 150 mL, beer 360 mL) 3. Individuals who had taken any medication within 10 days prior to the first day of dosing 4. Individuals who were deemed to be inappropriate to participate in the study by the investigator 5. Individuals who had participated of other clinical study or bioequivalence study within the 3 months prior to the first day of dosing 6. Individuals who donated whole blood within the 2 months, or blood components within 1 weeks prior to the first dose of the investigational product(s) 7. Individuals with hypersensitivity (include Vascular edema) to ingredients used in the investigational product(s) 8. Individuals with hereditary diseases of galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption etc. 9. Individuals with orthostatic hypotension 10. Individuals with severe hepatopathy 11. Individuals who had taken alpha-1 blocker 12. Individuals who had history of micturition syncope 13. Individuals with nephropathy 14. Elderly person 15. Individuals who had taken PDE5(phosphodiesterase-5) inhibitor 16. Individuals who had taken CYP3A4 inhibitor 17. Individuals who had taken antihypertensive drug(s)
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| AUCt of Chong Kun Dang Tamsulosin HCl Tablet and Harnal-D | Pre-dose (0 hour), post-dose 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24, 48 hours | Area under the Chong Kun Dang Tamsulosin HCl Tablet / Harnal-D concentration in blood-time curve from zero to final |
| Cmax of Chong Kun Dang Tamsulosin HCl Tablet and Harnal-D | Pre-dose (0 hour), post-dose 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24, 48 hours | The maximum Chong Kun Dang Tamsulosin HCl Tablet / Harnal-D concentration in blood sampling time t |
Countries
South Korea
Outcome results
None listed